Jeffrey S. Hatfield has been the CEO of Larimar Therapeutics since October 2017. He brings a significant background in the pharmaceutical industry, having previously led Vitae Pharmaceuticals from a startup in 2004 until it was acquired by Allergan in 2016....
Jeffrey S. Hatfield has been the CEO of Larimar Therapeutics since October 2017. He brings a significant background in the pharmaceutical industry, having previously led Vitae Pharmaceuticals from a startup in 2004 until it was acquired by Allergan in 2016. Before that, he spent two decades at Bristol-Myers Squibb in various roles, including working on important drugs like Plavix and Atripla. This depth of experience makes him well-suited for leading a company focused on innovative therapies. He holds an M.B.A. from The Wharton School and a bachelor’s degree in Pharmacy from Purdue University, where he also teaches as an adjunct professor. Despite facing challenges such as a clinical hold from the FDA, Hatfield has focused on advancing drug development and enhancing company strategy. His leadership is marked by a solid track record in both operations and strategic development in the biotechnology sector.